What you'll learn

Describe the optimal treatment approach to patients with oligometastatic cancers of the genitourinary tract
Explain the role of immunotherapy in the management of bladder and renal cancer
Determine how to incorporate genomic classifiers, multiple parametric MRI, and clinical parameters into selecting optimal patients with prostate cancer for active surveillance or other definitive management approaches
Apply Level 1 evidence on the use of novel treatment and surveillance options for patients with prostate, renal, bladder, or testicular cancer
Apply novel minimally invasive treatments for GU malignancies including prostate, bladder and kidney cancer
Use multiparametric MRI, fusion biopsy and novel markers in men at risk for prostate cancer

Course description

This is an accredited, livestreamed course offered by Brigham and Women's Hospital. This course is targeted to primary care physicians, specialty physicians, nurses, nurse practitioners, physician assistants, resident and fellow. This course may also be of interest to physicians who practice in radiation oncology, urology, radiology, pathology, oncology, and hematology, nuclear medicine, medical genetics and genomics, internal medicine,hospice and palliative medicine, healthcare education and leadership, geriatrics, and family medicine.

Select the Take Course button to view additional information on the course registration page.

*Register before Aril 12 to receive the discounted price.

Learn More

The Fredric G. Levin Lung Cancer Symposium

This course will outline the National Comprehensive Cancer Network’s (NCCN) accepted guidelines, and highlight updates to staging, treatment and indications for neoadjuvant and adjuvant therapy.

$100 - $150

Starts Mar 27